ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
View original at finance.yahoo.comLo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
Real-world evidence shows a five-year overall survival rate as low as 8% for patients with EGFR exon 20 insertion mutations, who have historically had limited targeted treatment options and poor outcomes.
60% confidenceSunvozertinib offers an oral, once-daily targeted treatment option recommended in clinical practice guidelines for patients with EGFR exon 20 insertion-mutated lung cancer who have progressed after platinum-based chemotherapy.
60% confidenceZEGFROVY is the only approved oral, single-agent, targeted therapy for patients with previously treated EGFR exon 20 insertion-mutated NSCLC following platinum-based chemotherapy.
60% confidenceThe US launch of ZEGFROVY marks an important step in AstraZeneca's commitment to the EGFR-mutated lung cancer community, bringing an oral, mutation-specific option to a distinct patient population with substantial unmet need.
60% confidenceThe ZEGFROVY launch expands AstraZeneca's commitment to addressing substantial unmet need across EGFR-mutated lung cancer with a proven portfolio of medicines targeting EGFR mutations.
60% confidenceIn the WU-KONG1B trial, ZEGFROVY showed a confirmed overall response rate of 46% (n=85; 95% CI 35, 57) and a median duration of response of 11.1 months among responders (n=39; 95% CI 8.2, NE); 72% of responders had duration of response of at least six months.
60% confidence